

May 26, 2022

To whom it may concern,

Company Name: Nichi-Iko Pharmaceutical Co., Ltd.
Representative Name: Yuichi Tamura, President & CEO
(Securities Code: 4541, Tokyo Stock Exchange)
Contact: Susumu Kanda, Executive Vice President,
President Office Director
(TEL. 076-432-2121)

Notice Regarding Approval at First Creditors Meeting on Business Turnaround ADR

As announced in the “Notice of Formal Application and Acceptance of Business Turnaround ADR” released May 13, 2022, we are in the process of business turnaround utilizing the specified certified dispute resolution procedure (the “Business Turnaround ADR”) under the Act on Strengthening Industrial Competitiveness, aimed at establishing a solid profit structure and drastically improving our financial position to reestablish growth going forward. On May 13, 2022, notice of temporary suspension of transactions effective as of May 13, 2022 was sent out to all partner financial institutions in the joint names of us and the Japanese Association of Turnaround Professionals (an association that has been certified as a certified dispute resolution business operator by the Minister of Justice and has been accredited as a specified certified dispute resolution business operator by the Minister of Economy, Trade and Industry). Following from this, a Creditors’ Meeting (First Creditors Meeting) was held to explain the outline of the draft business rehabilitation plan under the Business Turnaround ADR, and this meeting was attended by all partner financial institutions that are creditors subject to the procedure.

At the First Creditors Meeting, consent was obtained for the temporary suspension notice from all partner financial institutions, and approval was obtained regarding cessation of the temporary suspension at the end of the creditors’ meeting to approve the draft business rehabilitation plan.

We have swiftly secured a sufficient line of credit from our main bank, Sumitomo Mitsui Banking Corporation, to secure financing going forward, and all partner financial institutions have approved this credit facility.

Going forward, while advancing discussion with all partner financial institutions during the Business Turnaround ADR, we will ask the Japanese Association of Turnaround Professionals for investigation, guidance and advice from a neutral standpoint, and formulate a draft business rehabilitation plan. We aim to finalize the draft plan with the consent of all partner financial institutions at the creditors’ meeting held to pass a resolution for the draft rehabilitation plan.

End